NPPA and diabetic cardiomyopathy: Both ANP and α-MyHC are reliable markers of cellular hypertrophy and these findings show that the key features of diabetic cardiomyopathy (fibrosis and hypertrophy) are present in the low dose STZ-high fat model of type 2 diabetes and are prevented by 11β-HSD1 inhibition.